Press Releases 2019
Below you can access the latest press releases for 2019. Please note that some documents may refer to Liminal BioSciences' previous name Prometic Life Sciences Inc.
-
Liminal BioSciences comments on unusual market activity
-
Press Releases 2021
Read More -
AMF concludes its review of the refinancing transactions completed by Liminal in April 2019
The AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.
-
Liminal BioSciences to present at Piper Jaffray healthcare conference
The management team will provide a business overview and update at the Piper Jaffray 31st Annual Healthcare Conference at 08:10 ET on Wednesday, December 4, 2019 in New York, USA
-
Liminal BioSciences announces closing of divestiture of bioseparations division to KKR
LMNL announced today it has closed on the previously announced divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd. to KKR & Co.
-
LMNL presents new preclinical data on PBI-4050 and its effect on angio-proliferative pulmonary arterial hypertension
LMNL to present two scientific posters with new preclinical data for PBI-4050 and the treatment of pulmonary arterial hypertension (“PAH”) at the American Heart Association conference.
-
Liminal BioSciences to present at the Jefferies 2019 London healthcare conference
Members of the management team will provide a business overview and update at the Jefferies 2019 London Healthcare Conference at 18:00 GMT on Wednesday, November 20, 2019 in London, UK.
-
Liminal BioSciences announces effectiveness of registration statement on form F-10 and filing of prospectus supplement
LMNL announced today that its registration statement on Form F-10 (the “Registration Statement”), which was filed with the United States Securities and Exchange Commission (the “SEC”) on November 12
-
Liminal BioSciences to present at Stifel healthcare conference
LMNL management team will provide a business overview and update at the Stifel Healthcare Conference at 14:25 ET on Tuesday, November 19, 2019 in New York, USA.
-
Liminal BioSciences to commence trading common shares on NASDAQ
Trading is expected to commence on NASDAQ on Monday, November 18, 2019, under the ticker symbol ‘LMNL’.
-
Liminal BioSciences announces key appointment to its leadership team
LMNL announced today the addition of Moira Daniels as the new Head of Regulatory Affairs and Quality Assurance, to its senior leadership team.
-
Liminal BioSciences presents new preclinical data on PBI-4050 and NASH candidate PBI-4547
-
Liminal BioSciences reports its 2019 third quarter financial results and business highlights
-
Liminal BioSciences to report Q3 2019 results and hold conference call
-
Liminal BioSciences presents new preclinical data at ASN kidney week 2019
LMNL collaborators presented new preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology’s
-
Liminal BioSciences to divest bioseparations division to KKR
LMNL announced today the signature of a binding share purchase agreement for the divestment of its Isle of Man-based bioseparations business operated through its subsidiary Prometic Bioseparations Ltd
-
Liminal BioSciences announces upcoming presentations with new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting
Liminal BioSciences announces upcoming presentations new data on Pulmonary Arterial Hypertension at the 2019 AHA meeting
-
Liminal BioSciences announces upcoming presentations at The Liver Meeting 2019
Liminal Bio anannounced the presentation of three abstracts related to the Company’s pre-clinical development activities for the treatment of liver diseases at the The Liver Meeting 2019 of the AASLD
-
Liminal BioSciences announces upcoming presentations at ASN kidney week 2019
Liminal BioSciences and its’ collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at ASN Kidney Week.
-
Liminal BioSciences to present at H.C. Wainwright & Co. 3rd annual NASH investor conference
Liminal BioSciences announced today, that members of the management team will provide a presentation on PBI-4547 as a potential treatment for NASH
-
Prometic shareholders approve name change to Liminal BioSciences Inc.
Shareholders representing approximatively 87% of votes cast approved a special resolution authorizing the Company to amend its articles to change its name to Liminal BioSciences Inc.
-
Loading More...